Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...
Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy "Fucaso" (Equecabtagene Autoleucel) to the South Korean ...
GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...
Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...
In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...
MedPage Today on MSN
CAR-T Drug for Myeloma Hit With New Boxed Warning
Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...
Pharmaceutical Technology on MSN
GSK’s Blenrep gains FDA approval for myeloma treatment
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
GC Cell announced on the 29th that it has signed a contract with China's Nanjing IASO Biotechnology (IASO Bio) for the ...
The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...
The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback